CJC-TraC: Criminal Justice Coordinated Transitional Care

Sponsor
University of Wisconsin, Madison (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05376371
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
220
1
21

Study Details

Study Description

Brief Summary

This project aims to enroll 220 incarcerated individuals living with HIV, Hepatitis C (HCV), or history of substance misuse preparing for release into a pilot implementation study to test the feasibility and acceptability of an adapted Coordinated Transitional Care intervention in a Criminal Justice setting (CJC-TraC). Participants can expect to be on study for up to 6 months.

Condition or Disease Intervention/Treatment Phase
  • Other: CJC-TraC
N/A

Detailed Description

This protocol describes the second, implementation phase of a 5-year NIH-funded research project designed to evaluate post-incarceration health care utilization and outcomes for underserved people living with HIV, HCV and substance use disorder.

In the first study phase, conducted from 2020-21, the investigators analyzed Wisconsin Medicaid data to characterize the baseline level of outpatient care utilization for adults during their first 6 months after release from prison, and conducted formative research necessary to adapt an existing transitional care intervention, called C-TraC, to support individuals leaving prison.

The current project aims to enroll participants in a pilot implementation study to test the feasibility and acceptability of the adapted intervention in a criminal justice setting, which has been given the name "CJC-TraC."

Participants will be enrolled from one of two institutions:
  • men from Oakhill Correctional Institute (OCI)

  • women from Taycheedah Correctional Institute (TCI)

Primary Objectives: To evaluate the feasibility and acceptability of CJC-TraC when implemented in a state prison system.

Secondary Objectives: To gather preliminary evidence describing the effectiveness of CJC-TraC for improving the rate of outpatient care utilization.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
220 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Health Systems Innovations for Supporting Transitions of Care for Incarcerated People Living With HIV, Hepatitis C, and Substance Use Disorder
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: CJC-TraC Intervention

Incarcerated individuals with HIV, hepatitis C, or substance use disorder readying for release will enroll in the CJC-TraC intervention intended to assist in transitioning their health care.

Other: CJC-TraC
CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.

Outcome Measures

Primary Outcome Measures

  1. Feasibility Outcome: Number of participants who are enrolled and complete the baseline study assessment per month [at enrollment, up to 1 day]

    The investigators aim to enroll about 9 people per month over a 2 year study period. Results will be reported in total and per institution.

  2. Feasibility Outcome: Number of pre-release CJC-TraC intervention sessions completed with the nurse case manager for each participant [pre-release, up to 3 months]

    The investigators plan for 3 pre-release sessions with additional sessions as needed. The results will be reported in total and for each institution.

  3. Feasibility Outcome: Number of post-release telephone contacts between the CJC-TraC nurse case manager and study participants [post-release, up to 6 months]

    The investigators plan for 2 post-release sessions with additional sessions as needed.

  4. Feasibility Outcome: Proportion of study participants who are retained in follow-up for three months and complete the end-of-study assessment [within 3-months following release (up to 6 months on study)]

  5. Acceptability of Intervention Measure (AIM) Score [up to 3 months]

    The AIM is scored on a 5 point likert scale from 1 (completely disagree) to 5 (completely agree). Higher scores indicate increased acceptability of the measure.

  6. Intervention Appropriateness Measure (IAM) [up to 3 months]

    The IAM is scored on a 5 point likert scale from 1 (completely disagree) to 5 (completely agree). Higher scores indicate increased appropriateness of the measure.

Secondary Outcome Measures

  1. Number of non-emergency outpatient visits observed within 3-months following release [within 3-months following release (up to 6 months on study)]

  2. Number days until the first non-emergency outpatient visit following release. [within 3-months following release (up to 6 months on study)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Able to understand and speak in English

  • Plans to reside in Wisconsin after release

  • Eligible for Wisconsin Medicaid and willing to enroll prior to release

  • Has a history of one or more of the following: current HIV infection, current or past HCV infection, identified need for substance use related services based on Correctional Offender Management Profiling for Alternative Sanctions (COMPAS) assessment

  • Anticipated release date (must be within 6 months of review)

Exclusion Criteria:
  • Unable to provide informed consent form or impaired ability to make decisions

  • Planned discharge to another correctional facility or other carceral setting (e.g. release to jail or immigration detention center)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Wisconsin, Madison
  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Ryan Westergaard, MD, PhD, MPH, UW School of Medicine and Public Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT05376371
Other Study ID Numbers:
  • 2022-0398
  • 1R01DA047889-01A1
  • Protocol Version 3/1/2022
  • A534265
First Posted:
May 17, 2022
Last Update Posted:
Aug 25, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Wisconsin, Madison
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2022